Ionis Pharmaceuticals (IONS) Cash & Equivalents (2009 - 2026)

Ionis Pharmaceuticals' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $350.1 million for Q2 2026.

• In Q2 2026, Cash & Equivalents rose 17.75% year-over-year to $350.1 million; the TTM figure through Jun 2026 stood at $350.1 million (up 17.75% YoY), while the FY2025 annual figure was $372.3 million, up 53.78% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $350.1 million, up from $173.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $542.5 million in Q1 2022, with the low at $173.4 million in Q1 2026.
• The 5-year median for Cash & Equivalents is $336.5 million (2024), against an average of $342.0 million.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents plunged 68.19% in 2022, then jumped 53.78% in 2025.
• Ionis Pharmaceuticals' Cash & Equivalents stood at $276.5 million in 2022, then surged by 44.41% to $399.3 million in 2023, then sank by 39.37% to $242.1 million in 2024, then surged by 53.78% to $372.3 million in 2025, then fell by 5.96% to $350.1 million in 2026.
• Business Quant data shows IONS's Cash & Equivalents at $350.1 million in Q2 2026, $173.4 million in Q1 2026, and $372.3 million in Q4 2025.